BRNS
BarinthusยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BRNS Profile
Barinthus Biotherapeutics Plc
A clinical-stage biopharmaceutical company that develops immunotherapeutcs & vaccines for infectious diseases & cancer
Biological Technology
--
04/30/2021
NASDAQ Stock Exchange
105
12-31
Depository Receipts (Ordinary Shares)
20400 Century Blvd
Suite 210
Germantown
MD 20874
--
Barinthus Biotherapeutics plc was incorporated in January 2016 under the laws of England and Wales. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel T-cell immunotherapy candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The company has extensive clinical and preclinical stage treatment and prevention programs. The company's current treatment options include VTP-300 for the treatment of chronic hepatitis B infection, VTP-200 for the treatment of human papillomavirus infection, VTP-850 for the treatment of prostate cancer, VTP-600 for the treatment of non-small cell lung cancer, VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-related cancer. The latter two programs are designed to leverage the SNAPvaxTM platform. The company's current prevention programs include VTP-400 for the prevention of shingles or herpes zoster, and VTP-500 for the prevention of Middle East Respiratory Syndrome or MERS.
